The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making

26 Pages Posted: 19 May 2021

See all articles by Raymond C.W. Hutubessy

Raymond C.W. Hutubessy

Immunization, Vaccines and Biologicals (IVB) Department, World Health Organization (WHO)

Jeremy Addison Lauer

University of Strathclyde

Birgitte Giersing

World Health Organization

So Yoon Sim

World Health Organization

Mark Jit

London School of Hygiene & Tropical Medicine - Centre for Mathematical Modelling of Infectious Diseases

David Kaslow

PATH

Siobhan Botwright

World Health Organization

Date Written: May 7, 2021

Abstract

Objectives: The optimal development, use and impact of vaccines can be hindered by a number of seemingly distinct, but interrelated obstacles, which need to be addressed with a single over-arching strategy encompassing all stakeholders.

Methods: We propose a framework on the Full Value of Vaccines Assessments (FVVA) to guide the assessment and communication of the value of vaccines, to facilitate alignment among key stakeholders, and to improve decision-making around investment in vaccine development, policy, procurement, and introduction, for vaccines intended for use in LMICs.

Results: The framework outlines three functions of FVVA that will facilitate the achievement of afore-mentioned objectives. First, existing methods and tools need to be adapted to include broader benefits of vaccines as well as opportunity costs borne by stakeholders (assessment). Second, the increasing focus on the agency of stakeholders and country ownership of decision-making and priority setting should be reflected in the deliberative FVVA process to ensure introduction, equitable vaccine access and coverage, and sustainable impact (decision making). Finally, FVVAs should facilitate communication about the full value of vaccines and enhance alignment and coordination across diverse stakeholders (communication).

Conclusions: The framework on FVVA serves to guide stakeholders in organizing global-level efforts to invest in vaccines that are priorities for LMICs, and overcome hurdles to expand sustainable and equitable impacts of vaccines and immunization programs.

Note: Funding Statement: None reported.

Declaration of Interests: All authors declare no conflicts of interest in relation to this article.

Keywords: Vaccine, vaccination, immunization, research and development, decision making, priority setting, economic evaluations, health technology assessment, low and middle income countries

Suggested Citation

Hutubessy, Raymond C.W. and Lauer, Jeremy Addison and Giersing, Birgitte and Sim, So Yoon and Jit, Mark and Kaslow, David and Botwright, Siobhan, The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making (May 7, 2021). Available at SSRN: https://ssrn.com/abstract=3841999 or http://dx.doi.org/10.2139/ssrn.3841999

Raymond C.W. Hutubessy (Contact Author)

Immunization, Vaccines and Biologicals (IVB) Department, World Health Organization (WHO) ( email )

20 Avenue Appia
Geneva 27, CH-1211
Switzerland
0797939582 (Phone)

Jeremy Addison Lauer

University of Strathclyde ( email )

16 Richmond Street
Glasgow 1XQ, Scotland G1 1XQ
United Kingdom

Birgitte Giersing

World Health Organization ( email )

20 Avenue Appia
Geneva 27, CH-1211
Switzerland
0797939582 (Phone)
CH1211 (Fax)

So Yoon Sim

World Health Organization ( email )

20 Avenue Appia
Geneva 27, CH-1211
Switzerland
+41787233600 (Phone)

Mark Jit

London School of Hygiene & Tropical Medicine - Centre for Mathematical Modelling of Infectious Diseases ( email )

David Kaslow

PATH ( email )

2201 Westlake Avenue, Suite 200
Seattle, WA 98121
United States

Siobhan Botwright

World Health Organization ( email )

20 Avenue Appia
Geneva 27, CH-1211
Switzerland
0797939582 (Phone)
CH1211 (Fax)

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
567
Abstract Views
2,503
Rank
75,574
PlumX Metrics